Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Author(s) -
Richard J. Fitzgerald,
Laura Dickinson,
Laura Else,
Tom Fletcher,
Colin Hale,
Alieu Amara,
Lauren Walker,
Sujan Dilly Penchala,
Rebecca Lyon,
Victoria Shaw,
William Greenhalf,
Katie Bullock,
Lara Lavelle-Langham,
Helen Reynolds,
Wendy Painter,
Wayne Holman,
Sean Ewings,
Gareth Griffiths,
Saye Khoo
Publication year - 2022
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciac199
Subject(s) - prodrug , saliva , pharmacokinetics , nucleoside , medicine , nucleoside analogue , clinical trial , transmission (telecommunications) , covid-19 , coronavirus , respiratory system , pharmacology , gastroenterology , virology , chemistry , biochemistry , disease , infectious disease (medical specialty) , electrical engineering , engineering
ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at sites of SARS-CoV-2 transmission in twelve patients enrolled in AGILE CST-2 (NCT04746183). Saliva, nasal and tear concentrations were 3, 21 and 22% that of plasma. Saliva and nasal NHC concentrations were significantly correlated with plasma (p<0.0001).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom